Dr. Emmanuel S. Antonarakis

Dr. Emmanuel S. Antonarakis holds the William G. Clark Endowed Chair in Cancer Therapeutics at the University of Minnesota and co-leads the Masonic Cancer Center’s Prostate Cancer Program, where medical oncologists, urologic surgeons, radiation oncologists, pathologists, and genomic scientists meet each week to construct unified management plans for complex genitourinary malignancies. He serves on the National Cancer Institute Genitourinary Steering Committee’s Prostate Task Force and the National Comprehensive Cancer Network guideline panel, permitting rapid adoption of new evidence into institutional pathways. Administrative duties extend to mentoring trainees in the Division of Hematology, Oncology, and Transplantation and guiding electronic symptom-tracking initiatives that flag pain, fatigue, or urinary changes within hours. Keywords such as multidisciplinary prostate-cancer care coordination, comprehensive genitourinary oncology team, Masonic Cancer Center tumor board, evidence-based prostate-cancer guidelines, supportive oncology navigation improve search precision. Unified expertise and real-time monitoring shorten the interval from diagnosis to confident, individualized therapy.

 

Laboratory collaborations focus on the androgen-receptor splice variant 7 (AR-V7), DNA-repair defects, and prostate-specific membrane antigen biology. His group first demonstrated that AR-V7 in circulating tumor cells predicts resistance to enzalutamide and abiraterone—an observation now embedded in commercial assays and clinical algorithms. Flagship trials include PROfound, which established olaparib for homologous-recombination–deficient disease, and KEYNOTE-199, which paired pembrolizumab with enzalutamide in molecularly selected cohorts; ongoing studies examine lutetium-177 PSMA-617 radioligand therapy after androgen-receptor blockade. Keywords such as AR-V7 resistance biomarker, olaparib PROfound study, pembrolizumab DNA-repair prostate cancer, PSMA radioligand clinical trial, precision genomics in urologic oncology reinforce topical authority. Translational discoveries migrate quickly from bench to bedside, expanding targeted options for men with advanced cancer.

 

Authorship exceeds 240 peer-reviewed publications, and editorial appointments include Journal of Clinical Oncology and European Urology. Annual plenary invitations at ASCO, ESMO, and the Prostate Cancer Foundation distill cutting-edge data into practical guidance for clinicians and families, while Department of Defense and PCF Challenge grants fund mentorship of fellows exploring circulating tumor DNA kinetics and bispecific T-cell engagers. Community webinars with ZERO Prostate Cancer and culturally tailored podcasts translate genomics, nutrition, and survivorship science into everyday language. Keywords such as prostate-cancer education outreach, oncology fellowship mentorship, community genomics webinar, patient-friendly prostate-cancer resources, global oncology lectures enhance visibility. Clear, empathetic communication empowers shared decision-making and demystifies complex biology for diverse audiences.